THERAPY DOSSIER · th-58f31d0782ac

(-)-Myrtenol, a monoterpenoid

Nutraceutical · (-)-Myrtenol, a bicyclic monoterpenoid alcohol.

Evidence & regulatory context

Mechanism: (-)-Myrtenol, a bicyclic monoterpenoid alcohol.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30991046 ↗2019Reported benefit

(-)-Myrtenol accelerates healing of acetic acid-induced gastric ulcers in rats and in human gastric adenocarcinoma cells.

RatChemical/toxinWistarmaleoral administration50 and 100 mg/kg/dayafter ulcer induction, as treatment of the established chronic gastric ulcer

Model: Chronic gastric ulcer induced by serosal injection of 80% acetic acid

Oral (-)-myrtenol at 50 and 100 mg/kg/day for 7 days significantly decreased ulcer area and volume compared with vehicle-treated ulcer controls, with increased gastric mucin, collagen deposition and PCNA-positive cells, altered TNF-alpha, IL-1beta and COX-2 expression and reduced MMP-9 and MMP-2 ac…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…